Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GW4K
|
|||
| Drug Name |
Lopinavir + ritonavir + ribavirin + interferon beta-1b
|
|||
| Synonyms |
Aluviran + norvir + rebetol + betaseron
Click to Show/Hide
|
|||
| Drug Type |
Combination drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 3C-like protease (3CLpro) | Target Info | Inhibitor | [2] |
| COVID-19 RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04276688) Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | |||
| REF 2 | Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. | |||
| REF 3 | Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.